In postmenopausal women with overweight or obesity receiving tirzepatide, use of MHT is associated with superior weight loss outcomes.

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Click to read the study in AIM Relevant Reading: Tirzepatide once weekly for the treatment of obesity In-Depth [randomized controlled trial]: This post-hoc analysis of SURMOUNT-1, a phase 3, ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.